BiotechTube

BOTOX®/VISTABEL®

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Facial Corrections

Conditions

Facial Corrections, Facial Lines

Trial Timeline

Jan 5, 2023 → Oct 5, 2023

NCT ID
NCT05647551

About BOTOX®/VISTABEL®

BOTOX®/VISTABEL® is a approved stage product being developed by AbbVie for Facial Corrections. The current trial status is completed. This product is registered under clinical trial identifier NCT05647551. Target conditions include Facial Corrections, Facial Lines.

What happened to similar drugs?

3 of 7 similar drugs in Facial Corrections were approved

Approved (3) Terminated (0) Active (4)
✅BOTOXAbbVieApproved
✅OnabotulinumtoxinA + KYBELLAAbbVieApproved
✅Erenumab Prefilled SyringeAmgenApproved
🔄EMLA CreamSanofiPhase 3
🔄Botulinum toxin type AIpsenPhase 3
🔄FMX103 minocycline foam 1.5% + Vehicle foamVyne TherapeuticsPhase 3
🔄FMX103 minocycline foam 1.5% + Vehicle foamVyne TherapeuticsPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05647551ApprovedCompleted

Competing Products

13 competing products in Facial Corrections

See all competitors
ProductCompanyStageHype Score
BOTOXAbbVieApproved
43
OnabotulinumtoxinA + KYBELLAAbbVieApproved
47
Erenumab Prefilled SyringeAmgenApproved
43
RapamunePfizerPhase 1
29
EMLA CreamSanofiPhase 3
40
Diflucortolone valerate (BAY866146)BayerPre-clinical
23
Botulinum toxin type AIpsenPhase 3
37
IPN10200 + IPN10200 Placebo + DysportIpsenPhase 1/2
36
IPN59011 + Azzalure + PlaceboIpsenPhase 1
18
Fibrin Sealant with 4 IU/ml Thrombin, Vapor-Heated, Solvent Detergent Treated Containing Synthetic Aprotinin (FS VH S/D 4)BaxterPhase 2
32
Metyrosine + PlaceboBausch HealthPhase 2
21
FMX103 minocycline foam 1.5% + Vehicle foamVyne TherapeuticsPhase 3
30
FMX103 minocycline foam 1.5% + Vehicle foamVyne TherapeuticsPhase 3
30